< Back to previous page
Researcher
Bart De Geest
- Disciplines:Cardiology
Affiliations
- Centre for Molecular and Vascular Biology (Division)
Member
From1 Oct 1999 → Today
Projects
1 - 10 of 12
- Lipoprotein-targeted therapies for lipotoxic heart diseaseFrom1 Jan 2017 → 1 Jan 2021Funding: BOF - Doctoral projects, BOF - doctoral mandates
- High-density lipoprotein infusion therapy for heart failure with reduced ejection fraction and heart failure with preserved ejection fraction.From1 Oct 2015 → 30 Sep 2018Funding: FWO fellowships
- Therapeutic potential of high-density lipoproteins in heart failure with reduced ejection fractionFrom1 Oct 2014 → 13 Nov 2017Funding: Own budget, for example: patrimony, inscription fees, gifts
- The impact of metabolic stress on ventricular remodelling, myocardial substrate metabolism, and lipotoxicity in pressure overload-induced cardiomyopathy.From1 Jan 2014 → 31 Dec 2017Funding: FWO research project
- The impact of lipoproteins and of saturated fat on the development of heart failure: an experimental gene transfer and dietary intervention study.From1 Oct 2013 → 30 Sep 2017Funding: BOF - Concerted Research Project from 1994
- High density lipoprotein raising gene transfer strategies. Towards technological advances and new therapeutic niches.From1 Oct 2011 → 30 Sep 2014Funding: BOF - Other initiatives
- Evaluation of new predictors of transplant vasculopathy in heart transplant recipients.From1 Jan 2010 → 31 Dec 2013Funding: FWO research project
- The role of homocysteine in atherothrombosis revisited.From1 Oct 2009 → 29 Feb 2012Funding: FWO fellowships
- The impact of lipoprotein on stem cells.From1 Oct 2009 → 30 Sep 2015Funding: FWO fellowships
- Towards new therapeutic areas for HDL-targeted interventionsFrom1 Oct 2009 → 30 Sep 2013Funding: IWT personal funding - strategic basic research grants
Publications
11 - 20 of 91
- High-Density Lipoprotein-Targeted Therapies for Heart Failure(2020)
Authors: Bart De Geest
- Mesangial matrix expansion in a novel mouse model of diabetic kidney disease associated with the metabolic syndrome(2020)
Authors: Elisabet Van Loon, Maarten Naesens, Bart De Geest
- Administration of apo A-I (Milano) nanoparticles reverses pathological remodelling, cardiac dysfunction, and heart failure in a murine model of HFpEF associated with hypertension(2020)
Authors: Bart De Geest
- Thérapies ciblant les HDL pour l’insuffisance cardiaque à fraction d’éjection réduite/préservée(2020)
Authors: Bart De Geest
Pages: 20 - 25 - Cholesterol lowering attenuates pressure overload-induced heart failure in mice with mild hypercholesterolemia(2019)
Authors: Bart De Geest
Pages: 6872 - 6891 - Lipoprotein-targeted therapies for lipotoxic heart disease(2019)
Authors: Joseph Pierre Abou Msallem, Bart De Geest
- Cholesterol-Lowering Gene Therapy Prevents Heart Failure with Preserved Ejection Fraction in Obese Type 2 Diabetic Mice(2019)
Authors: Mudit Mishra, Bart De Geest
- Effective Treatment of Diabetic Cardiomyopathy and Heart Failure with Reconstituted HDL (Milano) in Mice(2019)
Authors: Ilayaraja Muthuramu, Mudit Mishra, Bart De Geest
- HDL dysfunction, function, and heart failure(2019)
Authors: Mudit Mishra, Ilayaraja Muthuramu, Bart De Geest
Pages: 293 - 294 - Racial/Ethnic Differences in Hypertension Prevalence: Public Health Impact versus Clinical Importance of Baseline Data of the HELIUS Study.(2018)
Authors: Bart De Geest, Mudit Mishra
Pages: 1911 - 1913